Table 2.
Overall and disease-specific survival analysis for the VGR-BC cohort.
| A. BIRC5/Survivin Protein Level [pg/g], Annotated Groups | |||
|---|---|---|---|
| 0, n = 66 | Range [0–100], 20 ± 31 | ||
| Low, n = 544 | Range [100–1000], 520 ± 247 | ||
| High, n = 235 | Range [1000–15,155], 2186 ± 137 | ||
| Survival probability | 27 years | 5 years | |
| DSS | Overall | p = 0.036 | p = 0.062 |
| High vs. 0 | HR 1.57 | p = 0.082 | |
| 95%CI [1.07–2.33], p = 0.023 | |||
| Low vs. 0 | HR 1.62 | HR 1.92 | |
| 95%CI [1.12–2.32], p = 0.011 |
95%CI [1.09–3.33], p = 0.022 |
||
| High vs. Low | p = 0.804 | p = 0.365 | |
| OS | Overall | p = 0.002 | p = 1.3 × 10−5 |
| High vs. 0 | p = 0.098 | p = 0.078 | |
| Low vs. 0 | p = 0.073 | HR 1.64 | |
| 95%CI [1.02–3.22], p = 0.037 |
|||
| High vs. Low | p = 0.873 | p = 0.653 | |
| Low + High, n = 779 | Range [100–15,151], 1023 ± 1400 | ||
| DSS | Low + High vs. 0 | HR 1.60 | HR 1.85 |
| 95%CI [1.11–2.31], p = 0.01 |
95%CI [1.05–3.22], p = 0.033 |
||
| OS | Low + High vs. 0 | p = 0.065 | HR 1.61 |
| 95%CI [1.01–2.56], p = 0.043 |
|||
| B. BIRC5/Survivin Protein Level [pg/g], Median Split | |||
| Low, n = 422 | Range [0–630.06], 312 ± 181 | ||
| High, n = 423 | Range [632.85–15,155], 1574 ± 1711 | ||
| Survival probability | 27 years | 5 years | |
| DSS | High vs. Low | HR 1.31 | HR 1.29 |
| 95%CI [1.10–1.56], p = 0.002 |
95%CI [1.01–1.64], p = 0.038 |
||
| DSS, ER-positive | High vs. Low | p = 0.260 | p = 0.823 |
| DSS, ER-negative | High vs. Low | HR 1.76 | HR 1.59 |
| 95%CI [1.24–2.49], p = 0.0013 |
95%CI [1.05–2.39], p = 0.027 |
||
| OS | High vs. Low | HR 1.38 | HR 1.12 |
| 95%CI [1.03–1.85], p = 0.033 |
95%CI [1.03–1.57], p = 0.028 |
||
| OS, ER-positive | High vs. Low | p = 0.367 | p = 0.269 |
| OS, ER-negative | High vs. Low | HR 1.38 | p = 0.134 |
| 95%CI [1.03–1.85], p = 0.031 |
|||
Survival was calculated by Mantel-Cox statistics. Protein levels in groups are indicated as mean ± std.